BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36112250)

  • 1. Insurance Authorization Barriers in Patients Undergoing Cytoreductive Surgery and HIPEC.
    Ong CT; Dhiman A; Smith A; Jose A; Kallakuri P; Belanski J; Sood D; Witmer HDD; Morgan RB; Turaga KK; Eng OS
    Ann Surg Oncol; 2023 Jan; 30(1):417-422. PubMed ID: 36112250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Misdiagnosis of appendiceal neoplasms as ovarian tumors: Impact of prior gynecologic surgery on definitive cytoreduction and HIPEC.
    Garland-Kledzik M; Maithel S; Jafari MD; Dehkordi-Vakil F; Chaudhry H; Dinicu A; Chang I; Krasnoff C; Gambhir S; Sheehan B; Pigazzi A
    Eur J Surg Oncol; 2022 Feb; 48(2):449-454. PubMed ID: 34454813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
    Abudeeb H; Selvasekar CR; O'Dwyer ST; Chakrabarty B; Malcolmson L; Renehan AG; Wilson MS; Aziz O
    Surg Endosc; 2020 Dec; 34(12):5516-5521. PubMed ID: 31993814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
    Chang SC; Fingerhut A; Chen WT
    Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Outcome of Icelandic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) abroad].
    Petursdottir A; Gunnarsson O; Valsdottir EB
    Laeknabladid; 2020 Jul; 106(7):344-348. PubMed ID: 32608356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancy: An Australian perspective with global application.
    McBride KE; Steffens D; Solomon MJ; Koh C; Ansari N; Young CJ; Moran B
    Eur J Surg Oncol; 2021 Apr; 47(4):828-833. PubMed ID: 32972815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era.
    Kelly ME; Murphy E; Keyes AM; Khan MF; Bolger JC; Grundy J; Conneely J; MacHale J; McCaffrey J; Cahill R; Moran B; Shields C; Mulsow J
    Ir J Med Sci; 2021 Nov; 190(4):1373-1377. PubMed ID: 33420573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
    JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
    Naffouje SA; O'Donoghue C; Salti GI
    J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, Risk Factors, and Outcomes from Conversion of Low-Grade to High-Grade Appendiceal Neoplasms for Patients Undergoing Multiple Cytoreductive Surgeries with Hyperthermic Intraperitoneal Chemotherapy.
    Mangieri CW; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    Ann Surg Oncol; 2022 Jan; 29(1):205-211. PubMed ID: 34455511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
    Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
    Clin Interv Aging; 2021; 16():559-568. PubMed ID: 33833505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?
    Narasimhan V; Cheung F; Waters P; Peacock O; Warrier S; Lynch C; Michael M; Ramsay R; Heriot A
    Surgeon; 2020 Oct; 18(5):287-294. PubMed ID: 31848069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?
    Strong EA; Livingston A; Gracz M; Peltier W; Tsai S; Christians K; Gamblin TC; Kersting K; Clarke CN
    J Surg Res; 2022 Oct; 278():31-38. PubMed ID: 35588572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Curr Oncol; 2020 Jun; 27(3):146-154. PubMed ID: 32669924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.